Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
b"At the end of 2022, adagrasib received its first FDA approval for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non\\u2013small cell lung cancer. Research is ongoing into adagrasib, a KRAS G12C inhibitor, for other tumors.\\n\\nIn today\\u2019s episode, we're joined by Jun Gong, MD, associate professor of medicine and the medical director of colorectal cancer in the Division of Medical Oncology at Cedars-Sinai Medical Center. During this interview, he discusses the mechanism of adagrasib, what other diseases it is being studied in, the latest data on adagrasib in colorectal cancer, and the importance of conducting genomic testing."